Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy

William E. Grizzle1 | Rick A. Kittles2 | Soroush Rais-Bahrami3 | Ebony Shah2 | George W. Adams4 | Mark S. DeGuenther4 | Peter N. Kolettis3 | Jeffrey W. Nix3 | James E. Bryant3 | Ravi Chinsky5 | James E. Kearns5 | Kerry Dehimer5 | Norma Terrin6 | Hong Chang6 | Sandra M. Gaston5,6

Abstract

Concerns about overtreatment of clinically indolent prostate cancer (PrCa) have led to recommendations that men who are diagnosed with low-risk PrCa be managed by active surveillance (AS) rather than immediate definitive treatment. However the risk of underestimating the aggressiveness of a patient's PrCa can be a significant source of anxiety and a barrier to patient acceptance of AS. The uncertainty is particularly keen for African American (AA) men who are about 1.7 times more likely to be diagnosed with PrCa than European American (EA) men and about 2.4 times more likely to die of this disease. The AA population, as many other populations in the Americas, is genetically heterogeneous with varying degrees of admixture from West Africans (WAs), Europeans, and Native Americans (NAs). Recommendations for PrCa screening and management rarely consider potential differences in risk within the AA population. We compared WA genetic ancestry in AA men undergoing standard prostate biopsy who were diagnosed with no cancer, low-grade PrCa (Gleason Sum 6), or higher grade PrCa (Gleason Sum 7-10). We found that WA genetic ancestry was significantly higher in men who were diagnosed with PrCa on biopsy, compared to men who were cancer-negative, and highest in men who were diagnosed with higher grade PrCa (Gleason Sum 7-10). Incorporating WA ancestry into the guidelines for making decisions about when to obtain a biopsy and whether to choose AS may allow AA men to personalize their approach to PrCa screening and management.

Key Words

African American, prostate biopsy, prostate cancer, West African ancestry
INTRODUCTION

Well-publicized concerns about overtreatment of clinically indolent prostate cancer (PrCa) have led to recommendations that men who are diagnosed with low-risk PrCa be managed by active surveillance (AS) rather than immediate definitive treatment. By deferring PrCa treatment until there is evidence of progression, the patient avoids the potential negative complications of surgery or radiation but accepts the risk that the aggressiveness of his PrCa may have been underestimated. This risk of underestimating a patient’s PrCa can be a significant source of anxiety and a barrier to patient acceptance of AS.1-3 The uncertainty about AS is particularly keen for African American (AA) men. Both incidence and mortality data show that the burden of PrCa is greater for AAs than for European Americans (EAs), with AAs about 1.7 times more likely to be diagnosed with PrCa than EAs and about 2.4 times more likely to die of this disease.4,5 Socioeconomic factors contribute to this disparity, but do not fully account for the observation that AA men are more likely than others to be diagnosed with more aggressive and life-threatening forms of PrCa.6,7 Recent studies suggest that AS criteria may need to be modified for AA men8,9,10 but there is no consensus.

The AA population, as many other populations in the Americas, is genetically heterogeneous with varying degrees of admixture from West Africans (WAs), Europeans (EUs), and Native Americans (NAs). Recommendations for PrCa screening and management rarely consider potential differences in risk within the AA population. To the extent that genetic factors contribute to the increased risk of PrCa in AA, WA genetic ancestry could potentially be used as a marker to better estimate an AA man’s personal PrCa risk. In this study, we tested the hypothesis that in AA men, WA genetic ancestry is associated with higher risk cancer on prostate biopsy.

METHODS

This study was approved by the University of Alabama at Birmingham IRB and by the Western IRB. Prostate biopsy patients were enrolled as study subjects by urologists affiliated with the University of Alabama at Birmingham and Urology Centers of Alabama. Prior to

| TABLE 1: Demographic and clinical characteristics of self-identified African American study subjects |
|---------------------------------------------------------------|

|                                | All Subjects | No Cancer on Biopsy | Diagnosed with GS 6 Cancer | Diagnosed with GS 7-10 Cancer |
|--------------------------------|--------------|---------------------|-----------------------------|-----------------------------|
| Number of Subjects             | 96           | 47                  | 21                          | 28                          |
| Age at biopsy                  |              |                     |                             |                             |
| Mean (SD)                      | 61.1 (7.6)   | 61.9 (7.0)          | 60.6 (9.0)                  | 60.2 (7.6)                  |
| Median                         | 61.5         | 63.0                | 61.0                        | 60.5                        |
| Gleason Sum (GS)               |              |                     |                             |                             |
| Grade Group 1                  | 21           | na                  | 21                          | 0                           |
| Grade Group 2                  | 16           | na                  | 0                           | 16                          |
| Grade Group 3                  | 5            | na                  | 0                           | 5                           |
| Grade Group 4-5                | 7            | na                  | 0                           | 7                           |
| NCCN Risk                      |              |                     |                             |                             |
| Low or very low                | 20           | na                  | 20                          | 0                           |
| Intermediate                   | 20           | na                  | 1                           | 19                          |
| High                           | 9            | na                  | 0                           | 9                           |
| Serum PSA (ng/mL)             |              |                     |                             |                             |
| Mean (SD)                      | 7.84 (7.40)  | 7.03 (6.10)         | 5.53 (2.37)                 | 11.03 (10.57)               |
| Median                         | 5.60         | 5.55                | 5.58                        | 6.20                        |
| Prostate Size (cc)             |              |                     |                             |                             |
| Mean (SD)                      | 49.0 (33.7)  | 58.8 (41.6)         | 41.7 (19.3)                 | 38.6 (21.7)                 |
| Median                         | 40           | 48.0                | 37.0                        | 34.6                        |
| PSA Density                    |              |                     |                             |                             |
| Mean (SD)                      | 0.21 (0.23)  | 0.16 (0.19)         | 0.15 (0.09)                 | 0.33 (0.31)                 |
| Median                         | 0.13         | 0.12                | 0.12                        | 0.21                        |

*One man with a PSA of 2196 ng/mL is excluded,

*For one man, prostate volume was missing from the clinical record,

*One man with a PSA of 2196 ng/mL and a second man for whom prostate volume was missing are excluded.
biopsy, consecutive eligible patients were asked if they wished to participate in the study and if they agreed they were enrolled with written informed consent. Elevated serum prostate-specific antigen (PSA) was the primary reason for the referral to a urologist for a diagnostic biopsy. A standard-of-care ultrasound-guided 12 core systematic biopsy was used to establish PrCa status as determined by a genitourinary pathologist examination of the hematoxylin and eosin (H&E)-stained biopsy slides. Demographic and clinical data were obtained by medical record review.

DNA prepared from biopsy cores with no histological evidence of cancer was used for ancestry genotyping. Variations in the distribution of single-nucleotide polymorphisms (SNPs) have been shown to differentiate human populations and panels of ancestry informative markers (AIMs) have been developed to distinguish populations of different biogeographic origins and to estimate population admixture. SNP genotyping was performed using the Sequenom MassARRAY genotyping platform with iPLEXchemistry according to manufacturer's recommendations. We used a panel of 105 unlinked AIMs described by Kosoy to estimate the proportion of WA, EU, and NA genetic ancestry for each of the study subjects. This panel of AIMs consists of 105 unlinked SNPs (Table S1). In our study population, the mean and median estimated NA genetic ancestry was only 3% and 2%, respectively, and NA ancestry was not included in the analyses.

In the statistical analyses, we first conducted a regression tree analysis to find the cut points of WA percent ancestry in predicting cancer status (cancer on biopsy). A three-category variable of WA percent ancestry (0.29-0.79, 0.79-0.87, and 0.87-0.99) was obtained as having the most predictive power of cancer status (Figure S1). We then conducted multivariate analyses to predict cancer on biopsy or high-grade cancer on biopsy using these categorical variables along with three established clinical variables (age, PSA, and prostate volume) as the predictors. First, we fit the logistic regression using the three WA percent ancestry categories alone (with 0.29-0.79 as the reference group) and then we added the three clinical variables into the model. A joint test of predicting cancer status for both the 0.79-0.87 and the 0.87-0.99 categories was also conducted. Finally, the receiver operating characteristic (ROC) analyses were performed using these predictors.

![FIGURE 1](image-url) AIMS estimates of individual WA, EU, and NA ancestry for 96 self-identified African American and 59 self-identified European American patients undergoing standard-of-care systematic prostate biopsy. The mean percentage of WA genetic ancestry for the AA men was 80% (SD 12%) and for the EA men was 7% (SD 12%), and the means were significantly different $P < .0001$. The mean percentage of EA ancestry was 89% (SD 14%) for the EA men and 17% (SD 12%) for the AA men, and the means were significantly different $P < .0001$. The mean percentage of NA ancestry was 3% (SD 4%) for AA men and 4% (SD 4%) for EA men (no significant difference). NA ancestry was not included in the analyses.
3 | RESULTS

The demographic and clinical characteristics of the study population are shown in Table 1. Of the 96 consecutive eligible AA study subjects, 49 (51%) were diagnosed with PrCa on a standard-of-care ultrasound-guided 12 core systematic biopsy. The overall Gleason grade was Gleason Sum (GS) 6 for 21 and GS 7-10 for 28 patients. Age at biopsy was not significantly different between the cancer-positive and cancer-negative patient groups or between the cancer-negative, GS 6 cancer, and GS 7-10 patient groups. Median prebiopsy PSA levels were not significantly different between the cancer-positive and cancer-negative patient groups or between the cancer-negative, GS 6 cancer, and GS 7-10 patient groups. One patient with PSA of 2196 ng/mL was removed from analyses involving PSA. The median prostate volume was 35.8 and 58.8 cc in the cancer-positive and cancer-negative groups and this difference was significant ($P = .007$) and consistent with benign enlargement of the gland in the PrCa-negative group. PSA density (PSA/prostate volume) is used to help correct for PSA increases due to benign prostatic enlargement, the median PSA density was 0.16 and 0.12 in the cancer-positive and cancer-negative groups, respectively, and this difference was significant ($P = .011$). The overall GS corresponded well with the National Comprehensive Cancer Network (NCCN) criteria for PrCa risk after biopsy, with all but one of the 21 men with GS 6 cancer meeting NCCN criteria for low- or very low-risk PrCa. NCCN criteria for PrCa risk include tumor volume, clinical stage, and prebiopsy PSA as well as GS.

Ancestry genotyping showed the expected admixture of WA and EU ancestry Figure 1. For the entire group of 99 self-identified AA patients, the mean estimated WA ancestry was 0.80. There were significant differences in the estimated WA ancestry between the diagnosis groups Figures 2 and 3, Tables 2 and 3. There was a significant difference ($P < .01$) between the estimated WA ancestries of the men who were biopsy-positive for cancer (0.83) and the men who were cancer-negative (0.77). Importantly, there was also a significant difference between the men diagnosed with GS 7-10 PrCa (0.85) and the men diagnosed with GS 6 or no cancer ($P < .01$).

% WA ancestry was evaluated as a predictor of GS 7-10 cancer in our AA subjects both as a single variable and in combination with age, PSA, and prostate size Figure 4 and Table 4. As a single variable, % WA ancestry was a significant predictor of cancer on biopsy, with the AA men of % WA ancestry greater than 87% showing a 4.6 higher odds of PrCa ($P = .004$) and 5.7 higher odds of GS 7-10 cancer ($P = .004$) than the AA men with greater than 20% admixture. AA men with % WA ancestry between 80% and 87% also showed increased PrCa risk compared to the AA men with greater than 20% admixture, with 2.8 higher odds for any cancer ($P = .05$) and 3.7 higher odds for GS 7-10 cancer ($P = .04$) than the AA men with greater than 20% admixture. For prediction of any cancer on biopsy, addition of WA to a base model that includes age, PSA, and prostate volume increases the model pseudo R square by 75% with $P = .0245$ for the joint test for two WA categorical variables. For predicting GS 7-10 cancer, addition of WA ancestry to the base model improves pseudo R square by 72% with $P = .0238$ for the joint test.

4 | DISCUSSION

The factors involved in increased risk for PrCa in AAs have generally been considered in comparison with EAs. In this study, we have focused on differences in potential PrCa risk factors within a population of self-identified AA men. % WA ancestry varies within the AA population and is higher for AAs in the southern United States than for AAs in the North and West. Our measures of PrCa risk are focused on the prostate biopsy, and specifically on the pathology diagnosis that is critical to guiding decisions about patient care. We

![Figure 2](image-url) Distribution of WA ancestry in African American men diagnosed with no cancer, low-grade cancer (GS = 6), and higher grade cancer (GS > 6) on standard biopsy. Median indicated by the horizontal lines.
found that WA ancestry was significantly higher in men who were diagnosed with PrCa on biopsy, compared to men who were cancer-negative, and highest in men who were diagnosed with GS 7-10 PrCa.

Because of the importance of biopsy GS in assessing cancer severity and thus in determining whether or not a patient should consider AS, we evaluated % WA ancestry as a predictor of GS 7-10 cancer in our AA subjects both as a single variable and in combination with other variables used clinically to make decisions about whether a patient should undergo prostate biopsy. For prediction of any cancer on biopsy, addition of WA to a base model that includes age, PSA, and prostate size increases the model pseudo R square by 75% with \(P = .0245\). For predicting GS 7-10 cancer, addition of WA ancestry to the base model improves pseudo R square by 72% with \(P = .0238\). Thus when considered in combination with age, PSA, and prostate size, % WA ancestry remained a strong predictor of both PrCa diagnosis and GS 7-10 cancer on biopsy.

Interestingly, in a study of 244 AA men from Chicago, Kittles and coworkers also found that % WA ancestry was associated with a higher risk of cancer on standard 12 core biopsy, but did not find an association between % WA ancestry and...
FIGURE 4 Receiver operating characteristic (ROC) curves comparing the base model (age, PSA, and prostate volume) with a model in which WA ancestry is added to the base model for prediction of any cancer on biopsy and for prediction of GS 7-10 PrCa on biopsy.

TABLE 4 Relationship between AIMs estimate of West African genetic ancestry and the probability of incident prostate on standard biopsy in self-identified African American (AA) patients. WA ancestry cut points between prostate cancer risk categories were determined by a regression tree analysis and odds ratios for category 3 (WA ancestry 0.872-0.990) and category 2 (WA ancestry 0.795-0.871) were determined relative to the reference group, category 1 with greater than 20% ancestry admixture (WA ancestry 0.294-0.790). For prediction of a diagnosis of cancer on biopsy, addition of WA to a bause model that includes age, PSA, and prostate volume increases the model pseudo R square by 75% with \( P = .0245 \) for the joint test for two WA categorical variables. For predicting GS 7-10 cancer, addition of WA ancestry to the base model improves pseudo R square by 72% with \( P = .0238 \) for the joint test.

| Odds Ratios and \( P \) Values for Cancer on Biopsy and GS 7-10 Cancer on Biopsy |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Cancer on Biopsy | GS 7-10 Cancer on Biopsy |
| Mean | Range | OR and \( P \) value | 95% CI | AUC (95% CI) | OR and \( P \) value | 95% CI | AUC (95% CI) |
| Model 1: Logistic regression on WA categorical variables\(^b\) | | | | | | | |
| WA 0.795-0.871 | 0.274 | 0.0-1.0 | 2.832 (0.0457) | 1.020, 7.865 | 3.706 (0.0380) | 1.075, 12.771 |
| WA 0.872-0.990 | 0.305 | 0.0-1.0 | 4.615 (0.0035) | 1.651, 12.901 | 5.687 (0.0042) | 1.732, 18.676 |
| Model 2: Multivariate logistic regression: age, PSA, prostate volume, WA ancestry | | | | | | |
| Age at biopsy (years) | 61.1 | 38.0-81.0 | 1.009 (0.7839) | 0.948, 1.074 | 1.011 (0.739) | 0.946, 1.082 |
| PSA (ng/mL) | 7.84 | 0.67-46.03 | 1.049 (0.2223) | 0.971, 1.133 | 1.115 (0.021) | 1.017, 1.224 |
| Prostate volume (cc) | 49.2 | 16.0-239.0 | 0.978 (0.0181) | 0.960, 0.996 | 0.981 (0.079) | 0.959, 1.002 |
| WA 0.795-0.871 | 0.274 | 0.0-1.0 | 2.939 (0.0547) | 0.979, 8.823 | 4.625 (0.032) | 1.144, 18.695 |
| WA 0.872-0.990 | 0.305 | 0.0-1.0 | 4.306 (0.0100) | 1.418, 13.072 | 6.339 (0.008) | 1.638, 24.531 |

\( N = 95 \), one patient with PSA = 2196 ng/mL was deleted from the analysis.

\( ^a \)ORs with \( P \) values less than 0.05 were considered statistically significant (bold type).

\( ^b \)The reference group for WA ancestry is the AA subjects whose WA ancestry was less than 0.79.
Gleason sum. A subsequent study of 287 Chicago-area prostate biopsy patients found that WA ancestry was not predictive of cancer or GS 7-10 on biopsy. Both of the Chicago studies used the same panel of ancestry genetic markers as used in our study of patients from Birmingham Alabama and, as expected, the median WA ancestry observed in the Birmingham patients (median 82.2, IQR 73.5-88.4) is greater than the median reported in the Chicago patients (median 78.4, IQR 69.7-92.2 and median 80.4; IQR 70.4-86.4 for Nyame et al and Nettey et al respectively). The difference between the association of WA ancestry and higher grade PrCa in the Birmingham and Chicago studies may reflect the limitations of study size. It is also possible that the association between WA ancestry and higher grade incident cancer in Birmingham reflects a greater prevalence of population-specific genetic or nongenetic factors that contribute to the development of more aggressive disease. Census records indicate that the place of birth for the majority of AAs in the Birmingham AL area is Alabama or Georgia, while AAs from Chicago have come from many different parts of the US and potentially are more genetically diverse. Lachance et al report that a relatively small number of genetic loci appear to drive elevated PrCa risk in men of WA descent. Comparing the relative prevalence of PrCa risk loci in AAs in Birmingham and Chicago might identify subtypes of PrCa that are more common in some AA communities than in others. In addition, an examination of potential interactions between WA ancestry and nongenetic risk factors, like obesity that are more prevalent in AAs in the South than in other parts of the US may reveal modifiable variables that can be incorporated into interventions. Access to care may also have a role in how PrCa genetic risk factors impact AA men. It should be noted that the higher levels of breast cancer-specific mortality in Latina women with higher NA genetic ancestry that was observed in a population-based study of patients from San Francisco and Northern California was not observed in Latina women from the Kaiser Permanente Northern California managed care health system.

One limitation to using prostate biopsies to evaluate PrCa risk is that standard-of-care systematic biopsies sample only a small portion of the gland and cancers can be missed. However, the impact of this inherent sampling error is likely to be similar across all of the study subjects. Current studies utilizing MR image-guided prostate biopsies that reduce sampling error are important for further evaluations of WA ancestry and incident PrCa. If the association between WA ancestry and risk of incident PrCa is confirmed, then incorporating WA ancestry into the guidelines for making decisions about when to biopsy and whether to choose AS may allow AA men to personalize their approach to PrCa screening and management. The commercial success of direct-to-consumer ancestry genotyping services suggests that the technical infrastructure is in place to make such a test widely available. What is needed now are the data essential to integrating genetic ancestry with other PrCa risk factors in order to determine how best to use this information to improve patient care.

CONFLICTS OF INTEREST
None.

ORCID
Sandra M. Gaston https://orcid.org/0000-0002-0564-0459

REFERENCES
1. Buethe DD, Pow-Sang J. Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer. J Natl Compr Canc Netw. 2012;10(9):1101-1110.
2. Kazer MW, Poutka SP, Latini DM, Bailey DE Jr. Psychosocial aspects of active surveillance. Curr Opin Urol. 2013;23(3):273-277.
3. Dall’Era MA. Patient and disease factors affecting the choice and adherence to active surveillance. Curr Opin Urol. 2015;25(3):272-276.
4. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute. 2016. http://seer.cancer.gov/csr/1975_2013/; based on November 2015 SEER data submission, posted to the SEER web site.
5. Negoita S, Feuer EJ, Mariotto A, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801-2814.
6. McGinley KF, Tay KJ, Moul JW. Prostate cancer in men of African origin. Nat Rev Urol. 2016;13(2):99-107.
7. Smith ZL, Eggener SE, Murphy AB. African-American prostate cancer disparities. Curr Urol Rep. 2017;18(10):81-90.
8. Gökce MI, Sündi D, Schaeffer E, Pettaway C. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis. 2017;20(2):127-136.
9. McClelland S 3rd, Jaboin JJ, Miini T. Is advocacy for active surveillance over definitive intervention in low-risk prostate cancer applicable to African American patients? Int J Radiat Oncol Biol Phys. 2017;99(5):1076-1077.
10. Qi R, Moul J. African American men with low-risk prostate cancer are candidates for active surveillance: the will-rogers effect? Am J Mens Health. 2017;11(6):1765-1771.
11. Kittles RA, Weiss KM. Race, ancestry, and genes: implications for defining disease risk. Annu Rev Genomics Hum Genet. 2003;4:33-67.
12. Al-Alem U, Rauscher G, Shah E, et al. Association of genetic ancestry with breast cancer in ethnically diverse women from Chicago. PLoS One. 2014;9(11):e112916.
13. Kosoy R, Nassir R, Tian C, et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat. 2009;30:69-78.
14. Baharian S, Barakatt M, Gignoux CR, et al. The great migration and African-American genomic diversity. PLoS Genet. 2016;12(5):e1006059.
15. Nyame YA, Murphy A, Batai K, et al. Generic ancestry and odds of prostate cancer diagnosis in African American and European American men. *J Clin Oncol*. 2016;34(suppl. 2):86.

16. Nettey OS, Walker AJ, Keeter MK, et al. Self-reported black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors. *Urol Oncol*. 2018;36(11):501.e1-501.e8.

17. Lachance J, Berens AJ, Hansen M, Teng AK, Tishkoff SA, Rebbeck TR. Genetic Hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent. *Cancer Res*. 2018;78(9):2432-2443.

18. Centers for Disease Control and Prevention (CDC). Differences in prevalence of obesity among black, white, and Hispanic adults - United States, 2006–2008. *MMWR Morb Mortal Wkly Rep*. 2009;58(27):740-744.

19. Fejerman L, Hu D, Huntsman S, et al. Genetic ancestry and risk of mortality among U.S. Latinas with breast cancer. *Cancer Res*. 2013;73(24):7243-7253.

20. Engmann NJ, Ergas JJ, Yao S, et al. Genetic ancestry is not associated with breast cancer recurrence or survival in U.S. Latina women enrolled in the Kaiser Permanente pathways study. *Cancer Epidemiol Biomarkers Prev*. 2017;26(9):1466-1469.

### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Grizzle WE, Kittles RA, Rais-Bahrami S, et al. Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy. *Cancer Med*. 2019;8:6915–6922. [https://doi.org/10.1002/cam4.2434](https://doi.org/10.1002/cam4.2434)